GreenBone Ortho today announces that it has achieved its aim of recruiting 15 patients into the GreenBRIC study. GreenBRIC study is a prospective, open-label, single-arm, first-in-human clinical investigation, in male and female patients, aged between 18 and 70 years, undergoing surgery to correct bone defects using GreenBone implant, specifically for iliac crest reconstruction. The primary objective of this study is to evaluate the safety of the GreenBone implant and the secondary objective is to evaluate its performance. The surgical procedure will be performed as per the standard of care at the investigational site.
The GreenBRIC study is conducted at Leeds University and the principal investigator is Professor Peter Giannoudis, professor at the School of Medicine, University of Leeds and head of the Trauma and Orthopaedic Department at Leeds General Infirmary (LGI). The study was approved by the Leeds West Research Ethics Committee, HRA (Health Research Authority), and MHRA (Medicines and Healthcare products Regulatory Authority).
Defects of the iliac crest most frequently result from the harvesting of bone grafts. Iliac crest bone grafts are considered the gold standard method in bone grafting procedures and they are widely used in a variety of orthopaedic, neurosurgical, and maxillofacial procedures to promote bone healing and restore bone defects. Harvested tricortical graft blocks are used to facilitate the fusion of joints (pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries (i.e., tibial plateau) and to fill in metaphyseal bone voids. Noteworthy, defects resulting from the harvesting of iliac bone grafts can be associated with significant morbidity and complications including infections, hematomas, hernias, persistent pain, and fracture of the ilium.
The GreenBone bone substitute, with its inherent physical and biomimetic properties, possesses a similar architectural structure to human bone, thus being a suitable material to be used for the treatment of the bone defect (3cm–4cm) induced from the harvested tricortical iliac crest, restoring, therefore, the pelvic anatomy and minimising the risk of chronic pain, haematoma formation, and herniation of the abdominal contents. The preliminary results from this study confirm the safety profile of the GreenBone 3D implant.
Professor Giannoudis said: ‘The GreenBone scaffold was found to be user-friendly and easy to apply during surgery. The bone defect in the iliac crest was well covered and continuity of the anatomy was achievable.
‘The scaffold proved to be a safe option to consider for restoration of the bone defect, taking into consideration that the other options to use include the allograft and xenograft (bovine) options. There was no increased pain observed but rather, based on the patient’s feedback, the symptoms claimed were well controlled and by four weeks there was no need for additional pain relief. Quality of life had significantly improved following surgery.
‘The healing process based on the radiological findings was associated with features indicative of scaffold integration and bone restoration. There were features of uniform healing with no signs of breakdown or fragmentation. No device deficiencies have been observed. We are continuing with the follow-up visits of the enrolled patients.’
‘We are very pleased to have achieved this important milestone,’ said CEO Lorenzo Pradella, ‘and we are confident that the final clinical results will support the market access of the product. We expect the results from the study to offer a safe alternative to the standard of care for bone loss given that our innovative 3D bone graft is proven to be as good as autograft, which requires a second surgical procedure to harvest bone from the patient’s iliac crest. These clinical data will play a key role in our commercial strategy to increase our share of the bone graft substitute market in Europe.’